How do I interpret T‑Spot.TB and QuantiFERON‑TB Gold test results for latent tuberculosis infection?

Interpretation of T-SPOT.TB and QuantiFERON-TB Gold Test Results

Both T-SPOT.TB and QuantiFERON-TB Gold tests are FDA-approved interferon-gamma release assays (IGRAs) that can be used interchangeably with or instead of the tuberculin skin test (TST) for diagnosing latent tuberculosis infection, with the choice depending on your specific clinical scenario and patient population 1.

Test Result Interpretation Framework

Basic Result Categories

Both IGRAs provide three possible outcomes:

• Positive: Indicates M. tuberculosis infection (either latent or active TB)
• Negative: Suggests absence of M. tuberculosis infection
• Indeterminate: Test failure requiring repeat testing or alternative approach

Key Interpretation Principles

For QuantiFERON-TB Gold:

• Positive when TB antigen-minus-nil ≥0.35 IU/mL
• Indeterminate results occur in approximately 1-11% of cases 2, 3
• Higher rate of indeterminate results in immunosuppressed patients and children <5 years 2

For T-SPOT.TB:

• Positive when spot count exceeds manufacturer's threshold (typically ≥6-8 spots)
• Indeterminate results occur in only 3% of cases 2
• More robust performance in immunosuppressed patients 2

Clinical Decision Algorithm

Step 1: Initial Test Selection

Choose based on patient characteristics:

• Immunosuppressed patients (on corticosteroids, biologics, chemotherapy): Prefer T-SPOT.TB due to lower indeterminate rate (3% vs 11%) 2
• Children <5 years: Prefer T-SPOT.TB to avoid age-related indeterminate results with QuantiFERON 2
• BCG-vaccinated individuals: Either IGRA is superior to TST; both show significantly fewer false-positives than TST 4, 2
• General screening/healthcare workers: QuantiFERON acceptable due to automation and convenience 3, 5

Step 2: Managing Indeterminate Results

If QuantiFERON is indeterminate:

• Perform T-SPOT.TB within 30 days, which resolves 84.8% of indeterminate cases 3
• Do NOT simply repeat QuantiFERON

If T-SPOT.TB is indeterminate:

• Consider repeat testing after addressing reversible causes (severe lymphopenia, acute illness)
• If persistently indeterminate in high-risk patient, treat as if positive

Step 3: Handling Discordant Results

When tests disagree (occurs in 12-23% of cases) 4:

QuantiFERON-positive/T-SPOT-negative:

• More common pattern 6
• In low TB prevalence populations, likely represents false-positive QuantiFERON 4
• Assess epidemiologic risk factors: TB exposure history, country of origin TB prevalence, chest X-ray findings
• If low risk and no exposure: consider negative
• If high risk or documented exposure: treat as positive

T-SPOT-positive/QuantiFERON-negative:

• Less common pattern
• T-SPOT may be more sensitive in close contacts 2
• Treat as positive if any TB risk factors present

TST-positive/Both IGRAs-negative:

• Likely false-positive TST from BCG vaccination or non-tuberculous mycobacteria 4
• Consider negative unless very high-risk exposure
• Battey skin test reactivity correlates with this pattern 4

Critical Pitfalls to Avoid

1. Do not use quantitative values alone to distinguish active from latent TB - substantial overlap exists even in elderly populations 7. Always correlate with clinical, radiographic, and microbiological data.

2. Do not assume concordance - in low-prevalence populations, only 11.4% of positive individuals are positive on all three tests (TST, QuantiFERON, T-SPOT) 4

3. Do not ignore immunosuppression status - immunosuppressive drugs differentially affect test performance; T-SPOT is more reliable 8, 2

4. Do not repeat the same IGRA for indeterminate results - switch to the alternative IGRA instead 3

Specific Population Considerations

Patients starting anti-TNF therapy:

• Perform both TST and IGRA simultaneously to maximize sensitivity 8
• Treat if either test is positive
• IGRAs show better specificity (QuantiFERON 85.7%, T-SPOT 73.5%) than TST (60.3%) in this population 9

Healthcare workers:

• Either IGRA acceptable for serial testing (no boosting effect unlike TST) 10, 5
• T-SPOT shows highest sensitivity (92%) and specificity (95.7%) in this population 5

Elderly patients:

• Both tests remain useful but quantitative values have limited discriminatory value for active vs latent disease 7
• Focus on qualitative positive/negative results combined with clinical assessment

Children:

• QuantiFERON detects more positives than T-SPOT overall (10.1% vs 7.4%) 6
• However, T-SPOT preferred in children <2 years due to fewer indeterminate results 2

Quality Control Considerations

Both tests require strict adherence to:

• Proper blood collection timing and technique
• Temperature maintenance during transport
• Processing within specified timeframes
• Laboratory proficiency testing 1